RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

Iranians have been struggling with a near-total internet blackout for nearly two weeks. Authorities shut down internet access ...